

---

CLINICAL PRACTICE GUIDELINES  
●  
LIGNES DIRECTRICES DE PRATIQUE CLINIQUE

---

## Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects

Margot I. Van Allen,\* MD, MSc, FRCPC (Med Gen), FCCMG, FAAP, FABMG;  
E. Clarke Fraser,† MD, PhD, DSc, FRCPC, FCCMG; Louis Dallaire,‡ MD, PhD, FCCMG, FRCPC;  
Judith Allanson,§ MB, ChB, MRCP, FCCMG, FABMG; D. Ross McLeod,|| MD, FRCPC, FCCMG;  
Eva Andermann,¶ MD, PhD, FCCMG; Jan M. Friedman,\* MD, PhD, FCCMG, FAAP, FABMG

**Objective:** To prevent the recurrence of neural tube defects (NTDs) in families at increased risk of having offspring with NTDs with the use of periconceptual folic acid supplementation.

**Options:** Genetic counselling and prenatal diagnosis of NTDs.

**Outcomes:** NTDs cause stillbirth, neonatal death and severe disabilities. The cost for medical care and rehabilitation in the first 10 years of life of a child with spina bifida cystica was estimated to be \$42 507 in 1987.

**Evidence:** The authors reviewed the medical literature, communicated with investigators from key studies, reviewed policy recommendations from other organizations and drew on their own expertise. A recent multicentre randomized controlled trial showed that among women at high risk of having a child with an NTD those who received 4 mg/d of folic acid had 72% fewer cases of NTD-affected offspring than nonsupplemented women. Two previous intervention studies also demonstrated that folic acid supplementation was effective in reducing the rate of NTD recurrence. Several retrospective studies support this conclusion.

**Values:** Recommendations are the consensus of the Clinical Teratology Committee of the Canadian College of Medical Geneticists (CCMG) and have been approved by the CCMG Board. The committee believes that primary prevention of NTDs is preferable to treatment or to prenatal detection and abortion.

**Benefits, harms and costs:** Folic acid supplementation should result in fewer NTDs among infants in Canada and ancillary savings in medical costs. The recommended dosage of folic acid is not known to be associated with adverse effects. Higher dosages of folic acid may make vitamin B<sub>12</sub> deficiency difficult to diagnose and may alter seizure frequency in patients with epilepsy due to drug interactions with anticonvulsants.

**Recommendations:** A minimum dosage of folic acid of 0.8 mg/d, not to exceed 5.0 mg/d, is recommended along with a well-balanced, nutritious diet for all women who are at increased risk of having offspring with NTDs and who are planning a pregnancy or may become pregnant. Supplementation should begin before conception and continue for at least 10 to 12 weeks of pregnancy.

**Validation:** These guidelines are similar to those of the Society of Obstetricians and Gynaecologists.

---

*From \*the Department of Medical Genetics, University of British Columbia, Vancouver, BC; †the McGill Centre for Human Genetics, McGill University, Montreal, Que.; ‡le Service de génétique médicale, Centre de recherche en pédiatrie, Hôpital Sainte-Justine, Montreal, Que.; §the Department of Paediatrics, University of Ottawa, Ottawa, Ont.; ||the Department of Medical Genetics, Alberta Children's Hospital, Calgary, Alta.; and ¶the Neurogenetics Unit, Montreal Neurological Hospital, Montreal, Que.*

*All of the authors are members of the Clinical Teratology Committee of the Canadian College of Medical Geneticists.*

*Reprint requests to: Dr. Margot I. Van Allen, Department of Medical Genetics, University Hospital-Shaughnessy Site, 4500 Oak St., Vancouver, BC V6H 3N1*

cologists of Canada, the US Centers for Disease Control and Prevention and the Department of Health in Britain.

**Sponsors:** These guidelines were developed by the CCMG Clinical Teratology Committee and endorsed by the Board of the CCMG. No funding for the development of these guidelines was obtained from any other sources.

**Objectif :** Prévenir, à l'aide de l'administration d'un supplément d'acide folique périconceptionnel, la récurrence des anomalies du tube médullaire dans les familles à risque élevé d'avoir des descendants ayant une anomalie du tube médullaire.

**Options :** Conseils génétiques et diagnostic prénatal d'anomalie du tube médullaire.

**Résultats :** Les anomalies du tube médullaire entraînent la mortinatalité, la mortalité néonatale et des invalidités sévères. Le coût des soins médicaux et de la réadaptation, au cours des 10 premières années de vie d'un enfant atteint d'hydromyélomélie externe rétro-médullaire, a été estimé à 42 507 \$ en 1987.

**Preuves :** Les auteurs ont revu la littérature médicale, ont communiqué avec les enquêteurs d'études clés, ont analysé les recommandations de politique d'autres organismes et se sont fiés à leur propre compétence. Un essai comparatif randomisé et multicentrique a démontré que, parmi les femmes à risque élevé d'avoir un enfant ayant une anomalie du tube médullaire, il y a 72 % moins de cas d'anomalie du tube médullaire des nouveau-nés, chez celles ayant reçu 4 mg/d d'acide folique que chez celles n'ayant pas reçu de supplément. Deux études antérieures sur le terrain ont aussi démontré que l'administration de suppléments d'acide folique est efficace pour réduire le taux de récurrence d'anomalies du tube médullaire. Plusieurs études rétrospectives appuient cette conclusion.

**Valeurs :** Les recommandations sont un consensus du Comité de tératologie clinique du Collège canadien de généticiens médicaux (CCGM) et ont été approuvées par le Conseil du CCGM. Le Comité croit que la prévention en première ligne des anomalies du tube médullaire est préférable au traitement ou à la détection prénatale et à l'avortement.

**Avantages, préjudices et coûts :** L'administration de suppléments d'acide folique devrait avoir pour résultat une diminution des anomalies du tube médullaire chez les nouveau-nés au Canada et, accessoirement, une diminution des coûts médicaux. On ne connaît pas d'effet adverse associé à la dose recommandée d'acide folique. Des doses plus élevées d'acide folique peuvent rendre plus difficile le diagnostic d'une déficience en vitamine B<sub>12</sub> et modifier la fréquence des attaques dues aux interactions médicamenteuses avec les anticonvulsivants chez les patientes atteintes d'épilepsie.

**Recommandations :** Une dose minimale de 0,8 mg/d d'acide folique, sans excéder 5,0 mg/d, est recommandée, conjointement avec un régime alimentaire bien équilibré et nutritif, pour toutes les femmes à risque élevé d'avoir des descendants ayant une anomalie du tube médullaire et qui ont l'intention de devenir enceintes ou pourraient devenir enceintes. L'administration d'un supplément devrait commencer avant la conception et se poursuivre pendant au moins 10 à 12 semaines de grossesse.

**Validation :** Ces lignes directrices sont similaires à celles de la Société des obstétriciens et gynécologues du Canada, des Centers for Disease Control and Prevention des États-Unis et du ministère de la Santé de Grande-Bretagne.

**Commanditaires :** Ces lignes directrices ont été mises au point par le Comité de tératologie clinique du CCGM et sanctionnées par le Conseil du CCGM. Aucune subvention destinée à leur mise au point n'a été obtenue à d'autres sources.

Neural tube defects (NTDs), including spina bifida, anencephaly and encephaloceles, occur in about 1.6 per 1000 births in British Columbia,<sup>1</sup> Alberta<sup>2</sup> and Ontario<sup>3</sup> and in up to 4.0 per 1000 births in Newfoundland<sup>4</sup> and Quebec.<sup>5</sup> The causes of NTDs are most commonly multifactorial, with a recurrence risk for a couple who have had a previous fetus or infant with an NTD of 2.1% in British Columbia,<sup>1,6</sup> 2.2% in Alberta,<sup>2</sup> 2.4% in Ontario,<sup>3</sup> 4.5% in Quebec<sup>7</sup> and 5% in Newfoundland.<sup>4</sup> Certain groups in Canada are at higher risk than others of NTD occurrence and recurrence.<sup>8</sup> Families in which NTDs are caused by monogenic disorders, chromosomal abnormalities or teratogenic ex-

posures have specific independent recurrence risks.<sup>9-11</sup>

Genetic counselling is available for prospective parents at increased risk of having a child with an NTD. This includes men and women who have had a child with an NTD, who are themselves affected with an NTD, who have a close relative with an NTD or who have a medical condition or are on medication that places their children at increased risk. Before folic acid supplementation, the only option available for high-risk couples who wished to reduce the chance of having children with NTDs was prenatal detection followed by abortion of an affected fetus.

There are important social and economic conse-

quences associated with NTDs. These severe congenital anomalies result in stillbirth, neonatal death and serious disabilities. In 1987 in Canada the estimated cost for hospital and rehabilitation services in the first 10 years of life for a child with spina bifida cystica was \$42 507.<sup>12</sup> The cost is even higher when continuing health problems, special education needs, modifications of home facilities and career options are considered.

## Methods

The Clinical Teratology Committee of the Canadian College of Medical Geneticists (CCMG) formulated guidelines to reduce the frequency of recurrence of neural tube defects (NTDs) in families that have children affected by NTDs. These recommendations are the result of a review of the medical literature; personal communication by members of the committee with investigators from key studies; a review of policy recommendations from other organizations; and committee members' expertise in teratology, embryology, medical genetics and public policy. Recommendations were formulated following discussion among the committee members. These guidelines are the consensus of the committee and have been approved by the CCMG Board.

The committee believes that the primary prevention of NTDs is preferable to surgical or medical treatment of NTDs or to prenatal detection with the option of abortion.

## Findings

Recent studies have provided strong scientific evidence that maternal periconceptional use of folic acid significantly reduces the risk of NTD recurrence for couples with a child who has an NTD.<sup>13-17</sup> The British Medical Research Council (MRC) Vitamin Study, a randomized double-blind clinical trial involving 1195 completed pregnancies in high-risk women from 33 centres, investigated the effect of a folic acid supplement of 0.4 mg/d and other vitamin supplementation in the prevention of NTDs.<sup>17</sup> The study showed 72% fewer cases of NTDs among the offspring of women who had received the folic acid than among those of the women in the control group (relative risk [RR] 0.28, 95% confidence interval [CI] 0.12 to 0.71). The recurrence rate was 3.5% in the control group and 1.0% in the group of women who received the folic acid for the first 6 weeks of pregnancy. The protective effect of folic acid supplementation was even greater when the women who stopped taking the folic acid during the first 6 weeks were excluded from the analysis; the recurrence rates were then 3.6% and 0.6% respectively (RR 0.17; 95% CI 0.05 to 0.59). The result in the group taking vitamins without folate (RR 0.80, 95% CI 0.32 to 1.72) was similar to the result in the group with no vitamin supplementation.<sup>17</sup>

The MRC Vitamin Study was preceded by two intervention studies showing that vitamin supplementation may be preventive. In one study 0.36 mg/d of folic acid was used<sup>14</sup> and in the other 4.0 mg/d.<sup>15</sup> Both dosages were effective in reducing the rate of recurrence of NTDs.

Previous case-control studies have demonstrated that pregnant women taking multivitamins containing folic acid are at lower risk of having children with NTDs than women not taking supplements.<sup>18-22</sup> One of these studies reported that equivalent amounts of dietary folic acid may be sufficient to reduce the risk.<sup>22</sup> In contrast, a case-control study of similar design involving women from California and Illinois demonstrated no protective effect of periconceptional vitamin supplementation.<sup>19</sup> The difference in results may reflect regional socioeconomic and cultural variations that lead to differences in dietary folate intake in the study populations. If this interpretation is correct, the effects of folic acid supplementation may be more apparent in regions of Canada with higher rates of occurrence of NTDs, such as Quebec and Newfoundland.

Folic acid appears to be responsible for preventing the recurrence of NTDs<sup>17</sup> and may also prevent their initial occurrence.<sup>18-22</sup> At the recommended dosages folic acid is not known to harm the fetus or pregnant woman.<sup>17,21</sup>

The optimal dosage of folic acid for reducing the risk of recurrence of NTDs is unknown. The dosage used in the MRC study was 4.0 mg/d,<sup>17</sup> whereas in other studies showing a reduction in the rate of NTD recurrence it was 0.36 to 5.0 mg/d.<sup>13-17</sup> The use of multivitamin supplements without adequate folate supplementation does not appear to reduce the risk of recurrence.<sup>17,21</sup> The dose of multivitamin preparations should not be doubled to increase folate supplementation because of the potential risk to the fetus and mother from excess vitamin A and D levels.<sup>21</sup>

To be effective in reducing the risk of NTDs folic acid supplementation should begin before conception and be continued for the first 10 to 12 weeks of pregnancy. Neurulation occurs in early embryogenesis, before most women are aware that they are pregnant. Closure of the neural tube is complete 26 to 28 days after conception or 5 to 6 weeks' menstrual age.

Although preliminary evidence suggests that the rate of occurrence of NTDs in all pregnancies is reduced by low-dosage supplementation of folic acid<sup>23</sup> it is not known whether folic acid supplementation can prevent NTD recurrence in offspring of parents with NTDs, of parents with a family history of NTDs in second- or third-degree relatives or of a father who has had a child with an NTD by a previous partner. It is not known whether folic acid supplementation will help prevent the recurrence of NTDs caused by monogenic disorders (e.g., the Meckel-Gruber syndrome and autosomal dominant spinal dysraphism), chromosomal abnormalities,

amniotic band disruptions or multiple congenital anomaly patterns (e.g., caudal regression sequence).

Infants of women with insulin-dependent diabetes mellitus have a 1% to 2% risk of NTDs.<sup>24</sup> It is not known whether folic acid supplementation will help prevent NTDs in these offspring. Women with folic acid deficiency because of intestinal disorders (small-intestine malabsorption or intestinal bypass) may be at increased risk of having offspring with NTDs<sup>25</sup> and may benefit from supplementation.

Epileptic women using certain anticonvulsants are at increased risk of having offspring with NTDs. Infants of women treated during pregnancy with valproic acid have an estimated risk of 1% to 2% for spina bifida.<sup>26</sup> Maternal carbamazepine intake may also be associated with a risk of 1% for spina bifida in offspring.<sup>27</sup> It seems prudent to determine whether epileptic women planning a pregnancy have folic acid deficiency. It is not known, however, whether folic acid supplementation would decrease the risk of NTDs in offspring of women using anticonvulsants. It may interfere with metabolism and uptake of anticonvulsants, and high dosages may therefore alter seizure frequency.

Some teratogens are suspected of causing NTDs by acting as folic acid antagonists or by being associated with inadequate folic acid availability to the embryo. Aminopterin and methotrexate cause specific multiple congenital anomaly patterns that may include NTDs<sup>28</sup> and are contraindicated in pregnancy. NTDs also appear to occur more frequently in association with fetal alcohol syndrome. Folic acid supplementation is not known to prevent NTDs or other teratogenic effects of alcohol on the embryos and fetuses of alcoholic women. The primary goal in such women is to avoid excessive alcohol ingestion during pregnancy.

## Recommendations

Women at increased risk of having a child with an NTD should be counselled about this risk and the options available to reduce it. For all women who have had an NTD-affected offspring and are planning a pregnancy or may become pregnant folic acid supplementation, 0.8 to 5.0 mg/d, is recommended in addition to a well-balanced, nutritious diet. Treatment should begin before conception and continue for at least 10 to 12 weeks of pregnancy.

Prenatal diagnosis based on previously published Canadian guidelines<sup>29</sup> is available to detect NTDs in high-risk pregnancies.

## Validation

These recommendations for folic acid supplementation are similar to those of the Society of Obstetricians and Gynaecologists of Canada,<sup>30</sup> the US Centers for Disease Control and Prevention<sup>21,31</sup> and the Department of Health in Britain.<sup>32</sup>

Previous studies have not determined the minimum effective supplementation dosage, although diets containing 0.2 mg/d folic acid do not appear to be effective.<sup>20,22</sup> The lower limit of 0.8 mg/d in the CCMG recommendation was selected because of the results of the Czeizel and Dudas study,<sup>23</sup> which demonstrated a reduction in the rate of NTDs among the infants of women at usual rather than increased risk who took folic acid supplements. The upper limit of 5.0 mg/d was selected because 5.0 mg is the dose per tablet currently available commercially.

## Implementation of recommendations

Programs should be implemented to educate physicians, other health care professionals and the public about the value of folic acid supplementation in preventing NTDs. Ongoing surveillance programs should monitor the prevalence of NTDs in fetuses and newborns. Basic and clinical research into the mechanisms by which folic acid prevents NTDs should be encouraged. In addition, clinical trials are needed to determine the effectiveness of folic acid in preventing the occurrence and recurrence of NTDs.

We thank Denise Koehn for nutritional advice, David Koehn for library research and Jeanette Davidson for editorial and secretarial assistance.

## References

1. Trimble BK, Baird PA: Congenital anomalies of the central nervous system: incidence in British Columbia, 1952-1972. *Teratology* 1978; 17: 43-49
2. Thunem NY, Lowry RB, Tucker BJ et al: Birth prevalence and recurrence rates of neural tube defects in southern Alberta in 1970-81. *Can Med Assoc J* 1988; 138: 819-823
3. Hunter AGW: Neural tube defects in eastern Ontario and western Quebec: demography and family data. *Am J Med Genet* 1984; 19: 45-63
4. Frecker M, Fraser FC: Epidemiological studies of neural tube defects in Newfoundland. *Teratology* 1987; 36: 355-361
5. Dallaire L, Melançon SB, Potier M et al: Date of conception and prevention of neural tube defects. *Clin Genet* 1984; 26: 304-307
6. McBride ML: Sib risks of anencephaly and spina bifida in British Columbia. *Am J Med Genet* 1979; 3: 377-387
7. Dallaire L, Michaud J, Melançon SB et al: Prenatal diagnosis of fetal anomalies during the second trimester of pregnancy: their characterization and delineation of defects in pregnancies at risk. *Prenat Diagn* 1991; 11: 629-635
8. Baird PA: Neural tube defects in the Sikhs. *Am J Med Genet* 1983; 16: 49-56
9. Holmes LB, Driscoll SG, Atkins LA: Etiologic heterogeneity of neural-tube defects. *N Engl J Med* 1976; 294: 365-369
10. Khoury MJ, Erickson JD, James LM: Etiologic heterogeneity of neural tube defects: clues from epidemiology. *Am J Epidemiol* 1982; 115: 538-548
11. Hall JG, Friedman JM, Kenna BA et al: Clinical, genetic, and epidemiological factors in neural tube defects. *Am J Hum Genet* 1988; 43: 827-837
12. Tosi LL, Detsky AS, Roye DP et al: When does mass screening

- for open neural tube defects in low-risk pregnancies result in cost savings? *Can Med Assoc J* 1987; 136: 255-265
13. Smithells RW, Sheppard S, Schorah CJ et al: Apparent prevention of neural tube defects by periconceptional vitamin supplementation. *Arch Dis Child* 1981; 56: 911-918
  14. Smithells RW, Nevin NC, Seller MJ et al: Further experience of vitamin supplementation for prevention of neural tube defect recurrences. *Lancet* 1983; 1: 1027-1031
  15. Laurence KM, James N, Miller MH et al: Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. *BMJ* 1981; 282: 1509-1511
  16. Vergel RG, Sanchez LR, Heredero BL et al: Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. *Prenat Diagn* 1990; 10: 149-152
  17. MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 1991; 338: 131-137
  18. Mulinare J, Cordero JF, Erickson JD et al: Periconceptional use of multivitamins and the occurrence of neural tube defects. *JAMA* 1988; 260: 3141-3145
  19. Mills JL, Rhoads GG, Simpson JL et al: The absence of a relation between the periconceptional use of vitamins and neural-tube defects. *N Engl J Med* 1989; 321: 430-435
  20. Milunsky A, Jick H, Jick SS et al: Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. *JAMA* 1989; 262: 2847-2852
  21. Use of folic acid for prevention of spina bifida and other neural tube defects — 1983-1991. *MMWR* 1991; 40: 513-516.
  22. Bower C, Stanley FJ: Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. *Med J Aust* 1989; 150: 613-618
  23. Czeizel AE, Dudas I: Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. *N Engl J Med* 1992; 327: 1832-1835
  24. Mills JL, Knopp RH, Simpson JL et al: Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. *N Engl J Med* 1988; 318: 671-676
  25. Martin RH, Nimrod C: Crohn's disease, folic acid, and neural tube defects (NTD) [C]. *BMJ* 1984; 289: 228
  26. Lammer EJ, Sever LE, Oakley GP Jr: Teratogen update: valproic acid. *Teratology* 1987; 35: 465-473
  27. Rosa FW: Spina bifida in infants of women treated with carbamazepine during pregnancy. *N Engl J Med* 1991; 324: 674-677
  28. Warkany J: Aminopterin and methotrexate: folic acid deficiency. *Teratology* 1978; 17: 353-358
  29. Wilson RD, Rudd NL: Canadian guidelines for prenatal diagnosis of genetic disorders: an update. *J Soc Obstet Gynaecol Can* 1993; 15 (suppl): 15-39
  30. Wilson RD, Van Allen MI: Recommendations on the use of folic acid for the prevention of neural tube defects. *Ibid*: 41-44
  31. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. *MMWR* 1992; 41: 3-7
  32. Calman K: *Folic Acid and the Prevention of Neural Tube Defects*, Health Publications, Dept of Health and Social Services, Heywood, Lancashire, England, 1992

## **Anaprox® DS 550 mg** **Anaprox® 275 mg**

(naproxen sodium)

### Indications:

Relief of mild to moderately severe pain, accompanied by inflammation such as musculoskeletal trauma, post-dental extraction, relief of post-partum cramping and dysmenorrhea.

### Contraindications:

Anaprox and Anaprox DS (naproxen sodium) are contraindicated in patients, with active ulcers or active inflammatory diseases of the gastrointestinal tract. They are also contraindicated in patients who have shown hypersensitivity to it or to naproxen. Since cross-sensitivity has been demonstrated, Anaprox or Anaprox DS should not be given to patients in whom ASA or other non-steroidal anti-inflammatory drugs induce the syndrome of asthma, rhinitis, or urticaria. Sometimes severe and occasionally fatal anaphylactic reactions have occurred in such individuals.

### Warnings:

Peptic ulceration, perforation and gastrointestinal bleeding, sometimes severe and occasionally fatal, have been reported during therapy with non-steroidal anti-inflammatory drugs (NSAID's) including Anaprox and Anaprox DS. Anaprox and Anaprox DS should be given under close medical supervision to patients prone to gastrointestinal tract irritation particularly those with a history of peptic ulcer, diverticulosis or other inflammatory diseases of the gastrointestinal tract.

Patients taking any NSAID including this drug should be instructed to contact a physician immediately if they experience symptoms or signs suggestive of peptic ulceration or gastrointestinal bleeding. These reactions can occur without warning at any time during the treatment. Elderly, frail and debilitated patients appear to be at higher risk from a variety of adverse reactions from NSAIDs. For such patients, consideration should be

given to a starting dose lower than usual. The safety of Anaprox and Anaprox DS in pregnancy and lactation has not been established and its use is therefore not recommended.

### Precautions:

**Anaprox or Anaprox DS (naproxen sodium) should not be used concomitantly with the related drug Naprosyn® (naproxen) since they circulate in plasma as the naproxen anion.**

**G.I. system:** If peptic ulceration is suspected or confirmed, or if gastrointestinal bleeding or perforation occurs Anaprox or Anaprox DS should be discontinued, and appropriate treatment instituted. **Renal effects:** Patients with impaired renal function, extracellular volume depletion, sodium restrictions, heart failure, liver dysfunction, those taking diuretics, and the elderly, are at greater risk of developing overt renal decompensation. Assessment of renal function in these patients before and during therapy is recommended. Naproxen sodium and its metabolites are eliminated primarily by the kidneys, and therefore, a reduction in daily dosage should be anticipated to avoid the possibility of drug accumulation in patients with significantly impaired renal function. Naproxen sodium should not be used chronically in patients having baseline creatinine clearance less than 20 ml/minute.

Peripheral edema has been observed, consequently, patients with compromised cardiac function should be kept under observation when taking Anaprox or Anaprox DS. Each Anaprox tablet contains approximately 25 mg of sodium and each Anaprox DS tablet contains approximately 50 mg of sodium. This should be considered in patients whose overall intake of sodium must be markedly restricted. As with other drugs used in the elderly or those with impaired liver function it is prudent to use the lowest effective dose. Severe hepatic reactions including jaundice and cases of fatal hepatitis have been reported with NSAIDs. The prescriber should be alert to the fact that the anti-inflammatory, analgesic and antipyretic effects of Anaprox or Anaprox DS (naproxen sodium) may mask the usual signs of infection. Periodic liver function tests and ophthalmic studies are recommended

for patients on chronic therapy. Caution should be exercised by patients whose activities require alertness if they experience drowsiness, dizziness, vertigo or depression during therapy with the drug. The naproxen anion may displace other albumin-bound drugs from their binding sites and may lead to drug interactions or interfere with certain laboratory tests. See product monograph for specific examples. The safety and efficacy of this drug in children has not been established and its use in children is therefore not recommended.

### Adverse reactions:

Adverse reactions which occur in >1% of patients include:

G.I.: heartburn, constipation, abdominal pain, nausea, diarrhea, dyspepsia, stomatitis and diverticulitis.

CNS: headache, dizziness, drowsiness, light-headedness, vertigo, depression and fatigue.

Skin: pruritus, ecchymoses, skin eruptions, sweating and purpura.

CVS: dyspnea, peripheral edema and palpitations.

Special Senses: tinnitus and hearing disturbances.

Others: thirst.

For additional adverse reactions please refer to the product monograph.

### Availability:

Anaprox® is available in OVAL-SHAPED, BLUE film-coated tablets of 275 mg in bottles of 100, 500 and 1000 tablets.

Anaprox® DS is available in OVAL-SHAPED, BLUE film-coated tablets of 550 mg in bottles of 100 tablets.

### Dosage:

Anaprox® 275 mg: Two tablets (550 mg) followed by one tablet (275 mg) every 6-8 hours as required.

Anaprox® DS: One tablet (550 mg) twice daily.

Maximum daily dose: 1375 mg.

Product monograph available on request.



Syntex Inc.\* Mississauga, Ont./Montréal, Qué.  
\*Reg. user of all ® trademarks.

